Overall, ADAM10 inhibitor treatment results in the restoration of membrane CD30 levels, which restored sensitivity to anti-CD30 monoclonal therapies used in HL, such as Iratumumab (64). Here, TNFRSF8 is linked to Hodgkins lymphoma.